Myles Brown, MD, is Director, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute and Emil Frei III Professor of Medicine, Harvard Medical School. Dr. Brown’s research is focused on providing a detailed understanding of the factors underlying the hormone dependence of breast and prostate cancers with the goal of developing new therapies and improving outcomes for patients. His lab identified the role of co-activators in steroid receptor action; elucidated the dynamic nature of co-regulator function; and defined steroid receptor cistromes. In 2010, together with Shirley Liu he founded the Center for Functional Cancer Epigenetics at the Dana-Farber with the goal of identifying epigenomic alterations in cancer including those that influence response to endocrine therapy and perturb the tumor immune microenvironment.